Every few months a founder asks me the same question: is the US market worth entering? My answer is always a version of the same thing — it is a real and enormous market, but nearly every company that underestimates its complexity ends in silence. The real question is not whether it is worth it. The real question is whether you actually understand how the market is structured, and whether you have the capability to win inside that structure today.
Why the US Market Is Both Irresistible and Unforgiving
The headline number is seductive. At over USD 180 billion, the US accounts for close to 40% of global medical device revenue. It is the single largest national market in the world. The logic many companies follow is straightforward: capture just 1% and you are looking at USD 1.8 billion in sales.
The flaw in that logic is not the arithmetic. It is the question the arithmetic ignores: on what basis would you capture that 1%, through whom, and how?
The US market’s first defining characteristic is that it is mature and fiercely competitive. Medtronic, Johnson & Johnson, Philips, Siemens Healthineers, and Abbott have spent decades building sales networks, clinical relationships, brand recognition, and compliance infrastructure inside this market. A Chinese company entering today is not walking into open territory — it is entering a battlefield that has already been exhaustively contested.
The second characteristic is that the US is a predominantly direct-sales market, though not uniformly so across categories. High-value capital equipment, surgical devices, and premium consumables typically require a direct sales force — procurement cycles are long, clinical education investment is substantial, and hospital relationships take years to develop. Distributors cannot carry those functions. Certain lower-acuity consumables and home-use devices offer more channel optionality, with GPOs, redistributors, and e-commerce all playing roles. But many Chinese companies enter the US without doing this category-level channel analysis, and simply replicate the distributor-led model they used in Southeast Asia or domestic China. That model does not transfer.
Three Structural Barriers That Exceed Most Companies’ Expectations
Even companies that understand the need for direct sales typically underestimate the specific structural obstacles they will encounter.
The GPO System
Hospital procurement in the US is largely mediated by Group Purchasing Organizations. The top five GPOs — Vizient, Premier, HealthTrust, Intalere, and Provista — collectively cover the vast majority of US hospital beds. If your product is not on a GPO contract, even a motivated hospital procurement team faces significant procedural friction in purchasing it. Getting onto a GPO contract is possible, but it requires time, third-party clinical validation, price competitiveness, and demonstrated demand. None of those elements can be shortcut.
Clinical Evidence Requirements
US physicians and hospital value analysis committees rely heavily on peer-reviewed literature, randomized controlled trial data, and academic endorsement when evaluating new products. This is not a soft preference — it directly affects GPO contract eligibility, insurance reimbursement coverage, and the credibility of your sales representatives in clinical conversations. Having a product that performs well is not equivalent to having a product with sufficient clinical evidence. In the US, those are two distinct things, and conflating them is a common and costly mistake.
Sustained Compliance Costs
FDA 510(k) or PMA registration is the entry ticket, not the finish line. The ongoing compliance burden — Medical Device Reporting (MDR), Unique Device Identification (UDI) system maintenance, localized quality management system audits, recall readiness — represents a sustained operational cost that many companies do not adequately model before entry. Layered on top are the legal risk dimensions specific to the US: product liability litigation, patent infringement exposure, and antitrust considerations. Any of these can terminate a US market program at any stage.
FDA clearance means you have entered the examination hall — not that you have graduated. The real competition begins after registration: clinical evidence, GPO negotiation, direct sales infrastructure, and legal compliance. Each requires continuous resource commitment.
How Mindray Built a Foothold in the US
Among Chinese MedTech companies, Mindray is the most instructive example of sustained US market presence. Its path has several features worth examining carefully.
It chose a structurally accessible entry point. Mindray did not begin by competing with Medtronic in high-acuity surgical suites at major academic medical centers. It entered through emergency monitoring and mid-tier care settings — environments where brand recognition requirements were lower, procurement cycles were shorter, and volume was consistent. This was not a permanent strategy; it was a sequenced one that allowed the company to win locally before attempting to compete on the full-market level.
It used acquisition to compress the local capability-building timeline. In 2006, Mindray acquired Datascope’s patient monitoring business. The transaction delivered more than a product line — it delivered a functioning local team, an installed service network, and a base of market recognition. Rather than building direct sales capability from scratch, Mindray purchased a system that was already operating on US soil. For companies that can identify comparable acquisition targets, this remains an underused entry mechanism.
It treated compliance as infrastructure, not a one-time cost. Mindray maintained sustained FDA compliance across multiple product lines and invested consistently in its US regulatory posture. That investment provided the foundation for GPO engagement and hospital procurement credibility. While other companies were still debating whether registration was necessary, Mindray had already operationalized compliance as a baseline capability.
Even so, Mindray’s US revenue remains modest relative to its global scale. The US is not its primary market. But its path there is the most disciplined one any Chinese MedTech company has walked — and the gap between Mindray and its peers illustrates how high the bar actually is.
What It Takes to Win in the US Market
Not every company needs to enter the US market. But for those that do, the following conditions are non-negotiable.
- Category-level channel analysis before market-level strategy. Whether your product category is suited to direct sales, GPO-mediated distribution, or a hybrid model must be determined at the strategic level — not discovered through failed execution in the field.
- Clinical evidence in place before market entry, not during. Peer-reviewed publications, ideally from US or European studies, should be available before commercial conversations begin. Entering without them places your sales team in a permanently defensive position.
- A credible path to direct sales capability. For most device categories, a distributor-dependent model will not generate sustainable revenue in the US. Companies need a realistic plan — whether through hiring, acquisition, or partnership — for building local sales and clinical support capacity.
- Long-duration capital commitment. The realistic payback horizon for US market investment is five to eight years. Organizations expecting material financial returns in three years will typically exhaust their runway before reaching the inflection point.
The US market rewards companies that are more professional and more patient than their competitors at every stage of the value chain. The barrier to entry is not just FDA registration — it is the full combination of clinical credibility, procurement access, sales infrastructure, and legal resilience.
What Most Companies Should Do Now
The US market is genuinely suited to companies that have already built meaningful brand and product credibility in other markets, have demonstrated the ability to operate a direct sales function, have the capital patience to sustain a long investment cycle, and whose product category aligns with US market structure.
For the majority of Chinese MedTech companies currently in early or mid-stage internationalization, the more pragmatic path is to consolidate in Europe or in priority Southeast Asian markets first — accumulating clinical evidence, direct sales experience, and brand foundation — before entering the US with the resources and credibility the market actually demands.
The US market will not disappear, and the opportunity window is not closing in the next two years. Premature entry without adequate preparation does not simply waste resources. It can damage brand credibility in ways that make a future, better-resourced re-entry meaningfully harder.
The question worth asking is not “when should we enter the US?” It is: what differentiated position could we realistically build in the US market, and do we have the capability to build it now? If neither question has a clear answer, the US is not yet the right place to concentrate your resources.
Copyright and Disclaimer
This insight is prepared by WExAct based on public information, industry observations and professional experience. It is intended for strategic, market research and business decision-making reference only, and does not constitute legal, financial, investment, regulatory, compliance or commercial advice. © WExAct Consulting. All rights reserved. Reproduction, excerpting or commercial use without authorization is prohibited.
